Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled multicenter study of Xiaoer Yinlian Granules in children with acute upper respiratory tract infection (wind-heat pattern)
CTR20262592Phase 2Active
- Sponsor
- Yili Pharmaceutical
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Xiaoer Yinlian Granules in upper respiratory infection (URI), sponsored by Yili Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
Xiaoer Yinlian Granules
03
Conditions
upper respiratory infection (URI)
Beyond the preview
Go deeper on CTR20262592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262592.